Research programme: heart surgery therapeutics - Phylogica/Baker IDI

Drug Profile

Research programme: heart surgery therapeutics - Phylogica/Baker IDI

Latest Information Update: 30 Apr 2010

Price : $50

At a glance

  • Originator Baker Heart Research Institute; Phylogica
  • Developer Baker IDI; Phylogica
  • Class Peptide fragments
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Ischaemic heart disorders

Most Recent Events

  • 19 Apr 2010 Early research is ongoing in Australia
  • 26 Jul 2006 Early research in Ischaemic heart disorders in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top